Drug
D0364 | Lonidamine
L
L01XX07 Lonidamine
[L01XX] Other antineoplastic agents
[L01X] OTHER ANTINEOPLASTIC AGENTS
[L01] ANTINEOPLASTIC AGENTS
[L] Antineoplastic and immunomodulating agents
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 138.1 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | 249 | |||||||
| RESPIRATION | 18.9 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | decrease | EC20 | 36 |
| RESPIRATION | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| GLYCOLYSIS | 249 | |||||||
| SWELLING | 660 µM | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | increase | EC20 | 36 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 18.9 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | inhibit | EC20 | 36 |
| Succinate dehydrogenase | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| Hexokinase-1 | 249 | |||||||
| Cytochrome c | > 800 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] H351 (95%): Suspected of causing cancer [Warning Carcinogenicity] H360 (95%): May damage fertility or the unborn child [Danger Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P264, P270, P281, P301+P312, P308+P313, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| 1-(2,4-Dichlorbenzyl)-indazole-3-carboxylic acid | 1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid | 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid |
| 1-[(2,4-DICHLOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBO | 1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid | 1-[(2,4-dichlorophenyl)methyl]-3-indazolecarboxylic acid |
| 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid | 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- | 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- (9CI) |
| 1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorobenzyl)- | 1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- | 1H-Indazole-3-carboxylicacid, 1-[(2,4-dichlorophenyl)methyl]- |
| 264L692 | 4CH-014644 | 50264-69-2 |
| AB0010495 | AB00597141_08 | AB00597141_10 |
| AB2000699 | AC-5626 | ACT02617 |
| AF 1890 | AF-1890 | AF1890 |
| AKOS012842739 | AM20060642 | API0003207 |
| AS-11653 | AX8006155 | BCP06555 |
| BDBM59775 | BIL0844 | BR-73119 |
| BRD-K78513633-001-03-3 | BRD-K78513633-001-06-6 | BRN 0894483 |
| C15H10Cl2N2O2 | CAS-50264-69-2 | CCG-204803 |
| CCRIS 3516 | CHEBI:50138 | CHEMBL1257030 |
| CS-2602 | CTK1H1686 | D07257 |
| DICA | DSSTox_CID_782 | DSSTox_GSID_20782 |
| DSSTox_RID_75787 | DTXSID5020782 | Dichlondazolic acid |
| Diclondazolic acid | Doridamina | Doridamina (TN) |
| EINECS 256-510-0 | EU-0100718 | FT-0650359 |
| HMS2234H24 | HMS3262O17 | HMS3268K09 |
| HMS3369I01 | HMS3412P05 | HMS3651F09 |
| HMS3676P05 | HY-B0486 | J90044 |
| KN-228 | KS-00000XLL | L 4900 |
| LP00718 | LS-7474 | Lonidamin |
| Lonidamina | Lonidamina [INN-Spanish] | Lonidamine (INN) |
| Lonidamine [BAN:INN] | Lonidamine [INN:BAN] | Lonidamine, mitochondrial hexokinase inhibitor |
| Lonidaminum | Lonidaminum [INN-Latin] | Lopac-L-4900 |
| Lopac0_000718 | MFCD00866285 | MLS000028822 |
| NCGC00015609-01 | NCGC00015609-02 | NCGC00015609-03 |
| NCGC00015609-04 | NCGC00015609-05 | NCGC00015609-06 |
| NCGC00015609-07 | NCGC00015609-08 | NCGC00015609-09 |
| NCGC00025244-01 | NCGC00025244-02 | NCGC00025244-03 |
| NCGC00259855-01 | NCGC00261403-01 | NSC-741419 |
| NSC-758419 | NSC741419 | NSC758419 |
| Pharmakon1600-01503225 | Q-201318 | Q3836670 |
| S-4929 | SBI-0050696.P002 | SC-75962 |
| SCHEMBL7134 | SMR000058467 | SR-01000075961 |
| SR-01000075961-1 | SR-01000075961-3 | SR-01000075961-6 |
| ST2414921 | SW219810-1 | TH-070 |
| TR-017970 | Tocris-1646 | Tox21_110181 |
| Tox21_110181_1 | Tox21_202306 | Tox21_500718 |
| U78804BIDR | UNII-U78804BIDR | WDRYRZXSPDWGEB-UHFFFAOYSA-N |
| Z1741977188 | ZINC1632 | ZX-AFC001293 |
| cid_39562 | lonidamine | s2610 |
| DrugBank Name | Lonidamine |
| DrugBank | DB06266 |
| CAS Number | 50264-69-2 |
| PubChem Compound | 39562 |
| KEGG Compound ID | x |
| KEGG Drug | D07257 |
| ChEBI | 50138 |
| ChemSpider | 36170 |
| BindingDB | 59775.0 |
| Wikipedia | Lonidamine |